HC Wainwright & Co. Reiterates Neutral on RAPT Therapeutics
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Neutral rating on RAPT Therapeutics (NASDAQ:RAPT).

April 10, 2024 | 10:19 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Neutral rating on RAPT Therapeutics.
The reiteration of a Neutral rating by a prominent analyst suggests no significant short-term price movement is expected. Analyst ratings can influence investor sentiment but a Neutral stance often indicates that the analyst sees the stock as fairly valued at its current price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100